These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8726107)

  • 1. Current topics in tardive dyskinesia in Japan.
    Inada T; Yagi G
    Psychiatry Clin Neurosci; 1995 Dec; 49(5-6):239-44. PubMed ID: 8726107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent research trends in diagnosis, treatment, and prevention of drug-induced extrapyramidal symptoms seen in psychiatric patients].
    Inada T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Oct; 16(5):181-5. PubMed ID: 8962437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of tardive dyskinesia in Japan.
    Inada T; Ohnishi K; Kamisada M; Matsuda G; Tajima O; Yanagisawa Y; Hashiguchi K; Shima S; Oh-e Y; Masuda Y
    Eur Arch Psychiatry Clin Neurosci; 1991; 240(4-5):250-4. PubMed ID: 1675874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tardive dyskinesia: current clinical issues.
    Burke RE
    Neurology; 1984 Oct; 34(10):1348-53. PubMed ID: 6148718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
    Lockwood JT; Remington G
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinergic medication for neuroleptic-induced tardive dyskinesia.
    Tammenmaa IA; McGrath JJ; Sailas E; Soares-Weiser K
    Cochrane Database Syst Rev; 2002; (3):CD000207. PubMed ID: 12137608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and epidemiologic aspects of tardive dyskinesia.
    Baldessarini RJ
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):8-13. PubMed ID: 2858483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of tardive dyskinesia in the elderly: rates and risk factors.
    Woerner MG; Alvir JM; Saltz BL; Lieberman JA; Kane JM
    Am J Psychiatry; 1998 Nov; 155(11):1521-8. PubMed ID: 9812112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyskinesia and neuroleptic exposure in elderly psychiatric inpatients.
    Sweet RA; Mulsant BH; Rifai AH; Zubenko GS
    J Geriatr Psychiatry Neurol; 1992; 5(3):156-61. PubMed ID: 1353963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural history of tardive dyskinesia.
    Gardos G; Cole JO; Haskell D; Marby D; Paine SS; Moore P
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):31S-37S. PubMed ID: 2906068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa.
    Patterson BD; Swingler D; Willows S
    Schizophr Res; 2005 Jul; 76(1):89-97. PubMed ID: 15927802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of tardive dyskinesia in a clinic population.
    Fleischhauer J; Kocher R; Hobi V; Gilsdorf U
    Psychopharmacology Suppl; 1985; 2():162-72. PubMed ID: 2860658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid improvement of neuroleptic-induced tardive dyskinesia with levetiracetam in an interictal psychotic patient.
    Chen PH; Liu HC
    J Clin Psychopharmacol; 2010 Apr; 30(2):205-7. PubMed ID: 20520300
    [No Abstract]   [Full Text] [Related]  

  • 18. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials.
    Tammenmaa IA; Sailas E; McGrath JJ; Soares-Weiser K; Wahlbeck K
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Nov; 28(7):1099-107. PubMed ID: 15610922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tardive dyskinesia: reversible and irreversible.
    Casey DE
    Psychopharmacology Suppl; 1985; 2():88-97. PubMed ID: 2860664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.
    van Harten PN; Hoek HW; Matroos GE; van Os J
    J Clin Psychiatry; 2006 Dec; 67(12):1920-7. PubMed ID: 17194270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.